Research

Hormonal

GLP-1 receptor agonists (GLP-1 RAs) are not cost-effective at current prices, requiring significant price reductions to meet standard willingness-to-pay thresholds.

GLP-1 RAs are clinically effective but not cost-effective at current prices. They should be used selectively (e.g., for those who cannot undergo surgery) and only if pricing aligns with their health benefits.

GoodRefutesHIGH confidence
At current pricing, GLP-1 RAs rarely meet accepted cost-effectiveness thresholds.
Yeon‐Ju Huh · Journal of Metabolic and Bariatric Surgery · 2025

Why this rating

Based on multiple economic modeling studies showing high ICERs.

Source

Cost-Effectiveness of Obesity Treatments: Glucagon-Like Peptide-1 Receptor Agonists, Endoscopic Sleeve Gastroplasty, and Metabolic/Bariatric Surgery

Yeon‐Ju Huh · Journal of Metabolic and Bariatric Surgery · 2025

DOI 10.17476/jmbs.2025.14.2.97

narrative_reviewCited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →